Myelodysplastic Syndrome Market Set for Strong Growth During the Forecast Period (2026-2036) as Targeted Therapies and Novel Treatment Approaches Reshape the Landscape | DelveInsight

The 7MM myelodysplastic syndrome (MDS) treatment market was valued at $4.3 billion in 2025, with approximately 43,000 incident cases, and is forecast to grow through 2036 as aging demographics, improved diagnosis and new therapies expand the treatment pool. Geron's imetelstat generated $51.8 million of Q1 2026 net revenue, up 8% sequentially, signaling early commercial momentum, although Bristol Myers Squibb's luspatercept retains a substantially larger share. Pipeline catalysts include Halia's FDA Fast Track designation for ofirnoflast, encouraging early BEXMAB data for Faron's bexmarilimab, and Phase III data showing Orca-T improved overall and relapse-free survival versus PTCy-based transplants.

Analysis

GERN is the only listed name in the dataset with a directly monetizing MDS asset, but the relevant debate is no longer launch validation; it is whether treatment duration, community-oncology uptake and payer access can support a revenue trajectory materially above the current quarterly run-rate. The commercial opportunity is concentrated in ESA-refractory, transfusion-dependent lower-risk patients, where durable transfusion independence can justify premium pricing, but REBLOZYL (BMY) retains a large installed base and physician familiarity. Near-term revenue upside therefore depends more on conversion and persistence than on broad MDS incidence growth.

RIGL's claimed strategic advantage should be discounted until its development rights, trial design and addressable MDS population are independently verified. Biomarker-restricted programs can generate strong response data without producing meaningful revenue if testing rates, label breadth or sequencing limit eligible patients; this is particularly relevant to targeted agents competing against broadly used hypomethylating and supportive-care regimens. For TAK and GSK, MDS is unlikely to move consolidated earnings, but successful assets could create bolt-on business-development pressure and raise valuations across small-cap hematology platforms.

The second-order risk for GERN is that a crowded pipeline does not need to displace imetelstat outright to compress its terminal-sales multiple: a safer oral anemia therapy or a regimen that moves earlier in the treatment algorithm would reduce duration and share. Over the next 1-3 months, quarterly net-sales growth, gross-to-net trends, infusion-center adoption and guidance are the cleanest catalysts; over 6-18 months, competitive trial readouts and reimbursement persistence matter more. The contrarian view is that the broad market-growth narrative is not investable by itself: this is a small, segmented market, so clinical differentiation and execution—not epidemiology—will determine equity outcomes.

Key Decisions for Investors

• Maintain or initiate a modest long GERN only ahead of the next earnings update if channel checks indicate sequential net-sales growth above 10% and management maintains full-year guidance; target 20-30% upside over 6-12 months versus a 15% stop on evidence of slowing new-patient starts or worsening gross-to-net.
• Use a GERN long / BMY short pair only as a small relative-value expression around commercial data, not a structural BMY short: GERN has concentrated upside to MDS penetration while BMY's diversified portfolio limits REBLOZYL-specific downside. Exit if GERN reports flat sequential demand or if BMY demonstrates sustained REBLOZYL share gains in ESA-refractory patients.
• Keep RIGL on a clinical-and-regulatory watchlist rather than buying the pipeline narrative. Upgrade only after confirmation of program ownership, a defined registrational path and efficacy that exceeds relevant standard-of-care benchmarks without incremental cytopenia or infection burden.
• Avoid treating TAK, GSK or broad biotech ETFs as direct beneficiaries; the potential MDS contribution is too immaterial to overcome larger pipeline, FX and capital-allocation drivers. Use any sector-wide move sparked by promotional market reports to add only to names with measurable commercial exposure.